Cerenome closed out the first half of 2026 having quietly rebranded, restructured its capital stack, and started billing on a commercial diagnostic test for the first time in the company's modern history. The company changed its name from Plus Therapeutics to Cerenome in early August. That was the opening move of a broader repositioning. The rebrand landed alongside a 1-for-25 reverse stock split that took effect in early April. A January public offering raised approximately $15 million in gross proceeds, and a new at-the-market equity distribution agreement with Canaccord Genuity provides up to $17.35 million in additional capacity. The combined effect of these moves is a company that has reset its share structure, raised its stockholders' equity back above Nasdaq's minimum requirement, and positioned itself to fund a commercial diagnostics launch alongside two Phase 2 clinical programs.
The central investment debate is whether the current market capitalization of approximately $21 million is pricing the stock as a diagnostics play with radiopharmaceutical optionality, or as a dilution machine that has not yet proven it can fund its way to clinical inflection. The stock trades near the bottom of its 52-week range, a spread of roughly $21 between the high and the low. That spread reflects the reverse split, the January offering, and a market that has assigned a low probability of the REYOBIQ program clearing regulatory hurdles. The going concern language in the latest filings makes explicit that the company cannot fund its operations without continued equity access. That qualification shapes how investors price the capital structure. The four variables that determine the thesis are: the pace of CNSide diagnostic revenue, the status of the ReSPECT-LM Phase 2 trial, the cost of the ongoing dilution cycle, and the company's ability to maintain Nasdaq listing compliance.
The falsifiable clock runs to Q1 2027, when the company expects ReSPECT-GBM Phase 2 data. The interim test is whether CNSide diagnostic billings can scale past the immaterial levels reported in the first half of 2026. A further test is whether the ReSPECT-LM multi-dose trial continues to enroll without dose-limiting toxicity, and whether the Canaccord distribution agreement continues to be the primary source of new capital. If the market is right, the stock is a low-conviction lottery ticket on a radiopharmaceutical that has not yet cleared Phase 2, funded by an ATM that dilutes existing holders at near the bottom of the trading range. If the market is wrong, the CNSide diagnostics business provides a cash-flow bridge that reduces the dilution burden and lets the REYOBIQ program mature on its own merits.